Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Alzheimer's Disease

Free Subscription Articles published in JAMA Retrieve available abstracts of 51 articles: HTML format

Single Articles

December 2025
1. KNOPMAN DS
   Valacyclovir and Symptomatic Alzheimer Disease-No Evidence for Benefit.
   JAMA. 2025 Dec 17. doi: 10.1001/jama.2025.20795.
   PubMed    
   
   
   
2. 
   Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: Research Summary.
   JAMA. 2025 Dec 17:e2522830. doi: 10.1001/jama.2025.22830.
   PubMed    
   
   
   
3. DEVANAND DP, Wisniewski T, Razlighi Q, Qian M, et al
   Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.
   JAMA. 2025 Dec 17:e2521738. doi: 10.1001/jama.2025.21738.
   PubMed     Abstract available
   
   
   
4. RUBIN R
   Alzheimer Disease Blood Test Cleared for Primary Care, but Questions Remain About Its Use.
   JAMA. 2025 Dec 5. doi: 10.1001/jama.2025.21573.
   PubMed    
   
   
   September 2025
5. ANDERER S
   Alzheimer Disease Exacerbated by Air Pollution, Study Suggests.
   JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13889.
   PubMed    
   
   
   
6. RUBIN R
   Trying to Unravel Why Alzheimer Disease Is More Common in Women.
   JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.16269.
   PubMed    
   
   
   
7. ANDERER S
   First Antiamyloid Injectable Approved for Early Alzheimer Disease.
   JAMA. 2025 Sep 26. doi: 10.1001/jama.2025.13885.
   PubMed    
   
   
   August 2025
8. RUBIN R
   Treating Alzheimer Disease With Antiamyloid Therapies-The Real-World Experience Grows.
   JAMA. 2025 Aug 22. doi: 10.1001/jama.2025.14180.
   PubMed    
   
   
   
9. HUNT V
   An Alzheimer Biomarker Is Elevated in Newborns-Dementia Researchers Want to Know How They Clear It.
   JAMA. 2025 Aug 8. doi: 10.1001/jama.2025.13588.
   PubMed    
   
   
   July 2025
10. CHEN KY, Ross JS, Cohen AB, Karlawish J, et al
    Demographic Data Supporting FDA Authorization of AI Devices for Alzheimer Disease and Related Dementias.
    JAMA. 2025 Jul 30:e2512779. doi: 10.1001/jama.2025.12779.
    PubMed    
    
    
    June 2025
11. MOSCOSO A, Heeman F, Raghavan S, Costoya-Sanchez A, et al
    Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.
    JAMA. 2025 Jun 16. doi: 10.1001/jama.2025.7817.
    PubMed     Abstract available
    
    
    
12. RUBIN R
    What to Know About the First FDA-Cleared Blood Test for Alzheimer Biomarkers.
    JAMA. 2025 Jun 13. doi: 10.1001/jama.2025.9013.
    PubMed    
    
    
    May 2025
13. ANDERER S
    Knowing Alzheimer Disease Risk May Reduce Lifestyle Change Motivation.
    JAMA. 2025 May 30. doi: 10.1001/jama.2025.7764.
    PubMed    
    
    
    January 2025
14. MINTZKER Y
    Blood Biomarkers to Detect Alzheimer Disease.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25294.
    PubMed    
    
    
    
15. PALMQVIST S, Hansson O
    Blood Biomarkers to Detect Alzheimer Disease-Reply.
    JAMA. 2025 Jan 23. doi: 10.1001/jama.2024.25297.
    PubMed    
    
    
    September 2024
16. DEVERKA PA, Lin GA, Phillips KA
    Payer Coverage Considerations for Alzheimer Disease Blood-Based Biomarker Tests.
    JAMA. 2024 Sep 30. doi: 10.1001/jama.2024.19084.
    PubMed    
    
    
    August 2024
17. RUBIN R
    A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
    JAMA. 2024 Aug 16. doi: 10.1001/jama.2024.13816.
    PubMed    
    
    
    July 2024
18. PALMQVIST S, Tideman P, Mattsson-Carlgren N, Schindler SE, et al
    Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care.
    JAMA. 2024 Jul 28:e2413855. doi: 10.1001/jama.2024.13855.
    PubMed     Abstract available
    
    
    
19. SALLOWAY S, Rowe C, Burns JM
    Are Blood Tests for Alzheimer Disease Ready for Prime Time?
    JAMA. 2024 Jul 28. doi: 10.1001/jama.2024.12814.
    PubMed    
    
    
    
20. LU Y, Pike JR, Chen J, Walker KA, et al
    Changes in Alzheimer Disease Blood Biomarkers and Associations With Incident All-Cause Dementia.
    JAMA. 2024 Jul 28:e246619. doi: 10.1001/jama.2024.6619.
    PubMed     Abstract available
    
    
    
21. HARRIS E
    FDA Greenlights Second Alzheimer Drug, Donanemab.
    JAMA. 2024 Jul 26. doi: 10.1001/jama.2024.13386.
    PubMed    
    
    
    June 2024
22. RUBIN R
    A Neurologist Learned He Had Alzheimer Disease 8 Years Ago-Here's What He Wants People to Know.
    JAMA. 2024 Jun 28. doi: 10.1001/jama.2024.10805.
    PubMed    
    
    
    May 2024
23. HARRIS E
    Study: 2 APOE4 Copies May Indicate Genetic Form of Alzheimer Disease.
    JAMA. 2024 May 31. doi: 10.1001/jama.2024.9649.
    PubMed    
    
    
    
24. THAMBISETTY M, Howard R
    Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering.
    JAMA. 2024 May 6. doi: 10.1001/jama.2024.7548.
    PubMed    
    
    
    April 2024
25. RUBIN R
    Could GLP-1 Receptor Agonists like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?
    JAMA. 2024 Apr 19. doi: 10.1001/jama.2024.1017.
    PubMed    
    
    
    March 2024
26. KO D, Pascual-Leone A, Shah SJ
    Use of Lecanemab for Patients With Cardiovascular Disease: The Challenge of Uncertainty.
    JAMA. 2024 Mar 15. doi: 10.1001/jama.2024.2991.
    PubMed    
    
    
    
27. HARRIS E
    Biomarker Changes Can Begin 18 Years Before Alzheimer Disease Diagnosis.
    JAMA. 2024 Mar 6. doi: 10.1001/jama.2024.1568.
    PubMed    
    
    
    February 2024
28. HARRIS E
    Aducanumab Combined With Focused Brain Ultrasound More Effective.
    JAMA. 2024;331:466-467.
    PubMed    
    
    
    
29. HARRIS E
    Commercial Blood Test May Identify Alzheimer Disease Brain Pathology.
    JAMA. 2024 Feb 7. doi: 10.1001/jama.2024.0175.
    PubMed    
    
    
    December 2023
30. POMARA N, Imbimbo BP
    Use of Donanemab in Early Symptomatic Alzheimer Disease.
    JAMA. 2023;330:2304.
    PubMed    
    
    
    
31. EVANS CD, Sims JR
    Use of Donanemab in Early Symptomatic Alzheimer Disease-Reply.
    JAMA. 2023;330:2304-2305.
    PubMed    
    
    
    November 2023
32. RAFII MS, Fortea J
    Down Syndrome in a New Era for Alzheimer Disease.
    JAMA. 2023 Nov 22. doi: 10.1001/jama.2023.22924.
    PubMed    
    
    
    September 2023
33. RUBIN R
    Who Should-and Can-Get Lecanemab, the New Alzheimer Disease Drug?
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.14443.
    PubMed    
    
    
    
34. ODOUARD IC, Socal MP, Anderson GF
    Role of Registries in Medicare Coverage of New Alzheimer Disease Drugs.
    JAMA. 2023 Sep 27. doi: 10.1001/jama.2023.17131.
    PubMed    
    
    
    
35. RUBIN R
    Consumers Can Now Buy a Blood Test to Evaluate Their Alzheimer Disease Risk, but Should They?
    JAMA. 2023 Sep 13. doi: 10.1001/jama.2023.17685.
    PubMed    
    
    
    August 2023
36. HARRIS E
    Study: Identifying Lewy Body Disease Before Symptoms.
    JAMA. 2023;330:686.
    PubMed    
    
    
    July 2023
37. HARRIS E
    MIND Diet No Better Than Control for Adults at Risk of Dementia.
    JAMA. 2023 Jul 26. doi: 10.1001/jama.2023.13134.
    PubMed    
    
    
    
38. HARRIS E
    Alzheimer Drug Lecanemab Gains Traditional FDA Approval.
    JAMA. 2023 Jul 19. doi: 10.1001/jama.2023.12548.
    PubMed    
    
    
    
39. SIMS JR, Zimmer JA, Evans CD, Lu M, et al
    Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
    JAMA. 2023 Jul 17:e2313239. doi: 10.1001/jama.2023.13239.
    PubMed     Abstract available
    
    
    
40. ROSENTHAL MB
    Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11702.
    PubMed    
    
    
    
41. MANLY JJ, Deters KD
    Donanemab for Alzheimer Disease-Who Benefits and Who Is Harmed?
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11704.
    PubMed    
    
    
    
42. RABINOVICI GD, La Joie R
    Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11703.
    PubMed    
    
    
    
43. WIDERA EW, Brangman SA, Chin NA
    Ushering in a New Era of Alzheimer Disease Therapy.
    JAMA. 2023 Jul 17. doi: 10.1001/jama.2023.11701.
    PubMed    
    
    
    
44. HARRIS E
    More Lean Muscle Might Reduce Alzheimer Disease Risk.
    JAMA. 2023 Jul 12. doi: 10.1001/jama.2023.12544.
    PubMed    
    
    
    June 2023
45. HARRIS E
    CMS Will Cover Alzheimer Drugs With Traditional FDA Approval.
    JAMA. 2023 Jun 14. doi: 10.1001/jama.2023.10400.
    PubMed    
    
    
    
46. HARRIS E
    Brain Cell Biomarker for Preclinical Alzheimer Disease Identified.
    JAMA. 2023 Jun 7. doi: 10.1001/jama.2023.9928.
    PubMed    
    
    
    May 2023
47. HARRIS E
    FDA Greenlights First Drug for Agitation Related to Alzheimer Disease.
    JAMA. 2023 May 24. doi: 10.1001/jama.2023.9153.
    PubMed    
    
    
    
48. MARCUS R
    New Alzheimer Disease Drugs, Long COVID and the Central Nervous System, and a Nasal Spray for Migraines-Highlights From the 2023 American Academy of Neurology Conference.
    JAMA. 2023 May 10. doi: 10.1001/jama.2023.4389.
    PubMed    
    
    
    March 2023
49. HARRIS E
    Blood Biomarker Helps Distinguish Vascular Dementia.
    JAMA. 2023;329:969.
    PubMed    
    
    
    February 2023
50. HARRIS E
    Healthful Lifestyle May Slow Memory Loss, Even for APOE Gene Carriers.
    JAMA. 2023;329:622.
    PubMed    
    
    
    October 2021
51. EMANUEL EJ
    A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    JAMA. 2021;326:1367-1368.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.